Nuclera extends Series C to $87 million to advance antibody engineering
UK-based Nuclera, a biotech accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery System, has announced a $12 million financing extension, bringing the company’s total Series C funding to $87 million.
Nuclera claims to be solving one of the most pressing bottlenecks in biologics discovery, the slow, fragmented, and resource-intensive process of synthesising full-format antibodies.
The company says that its success in membrane proteins, one of the most challenging protein classes, combined with microfluidic expertise, places it in a unique position to transform antibody development workflows.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze